Screening and treating H. pylori to prevent gastric cancer in young adults
Official title: Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults
Run by University of Latvia · NCT06275204 · Data updated 2026-11-12
This study is testing if screening and treating young adults for H. pylori can help prevent gastric cancer in people aged 30-34 in several European countries.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years to 34 Years |
| Sex | All |
| Enrollment | 6800 (estimated) |
| Sponsor | University of Latvia Academic / other |
| Locations | 7 sites (Zagreb, City of Zagreb and 6 other locations) |
| Status | Recruiting |
| Started | March 4, 2024 |
| Main results expected | October 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | March 5, 2024 |
| Trial ID | NCT06275204 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are young adults aged 30-34 who have not previously been treated for H. pylori infection.
✕Probably not a fit
Patients with mental or developmental limitations, a history of gastric resection, or those who have previously been treated for H. pylori infection may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the feasibility and effectiveness of a population-based H. pylori test-and-treat strategy for preventing gastric cancer among young adults aged 30-34 in several European countries. It will involve testing 6,800 participants for H. pylori infection and assessing the acceptance and outcomes of various eradication therapies. The findings could inform the establishment of a national program for gastric cancer prevention, potentially reducing the incidence and burden of the disease in the long term.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of gastric cancer in young adults through early detection and treatment of H. pylori infection.
How similar studies have gone: While this specific approach is novel in Europe, similar strategies have shown promise in other regions for reducing gastric cancer incidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Young adults (generally 30 - 34 years of age) Exclusion Criteria: * Patients with mental or developmental limitations who cannot provide a fully-informed consent to participate (based on the assessment from research or patient's personal physician team) * Previously treated H. pylori infection * History of partial or total gastric resection due to benign or malign lesions
Where it's running
-
University Hospital Centre Zagreb
Zagreb, City of Zagreb, Croatia Recruiting -
Clinical Hospital Center Rijeka
Rijeka, Croatia Recruiting -
Beacon Hospital
Dublin, Ireland Recruiting -
Wroclaw Medical University
Wroclaw, Poland Recruiting -
Iuliu Hatieganu University of Medicine and Pharmacy
Cluj-Napoca, Cluj, Romania Recruiting -
National Institute of Public Health, Slovenia
Ljubljana, Slovenia Recruiting
Show 1 more location
-
Clinical and Preventive Medicine of the University of Latvia
Riga, Latvia Not yet recruiting
Study contacts
- Study coordinator: Principal Investigator of the Study - Bojan Tepeš (National Institute of Public Health, Slovenia), Prof., MD
- Email: bojan.tepes@siol.net
- Phone: 0038641325916
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Carminal for H. pylori gastritis
This trial will test if taking 30 ml daily of the Aloe vera–based supplement Carminal together with standard H. pylori therapy helps adults with H. pylori–positive gastritis heal their stomach lining better than standard therapy plus placebo.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.